Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Test At Home Pte. Ltd | UNKNOWN |
| National University of Singapore | OTHER |
Not provided
Not provided
Not provided
Not provided
Nasopharyngeal Swabs (NPS) used to test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection can cause mild to severe discomfort in addition to increasing the risk of transmission. The present study evaluates Test At Home's proprietary self-collection method based on a chewable buccal cavity swab ("lollipop") that stimulates oral fluid collection. The novel method is compared against a contemporary nasal swab collected by a qualified healthcare worker.
Nasopharyngeal Swabs (NPS) are used to test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. For this, a swab is inserted deep into the back of the nose to collect a sample. It can cause discomfort for most people. It also increases the risk of transmission and other challenges. The present study aims to develop a more convenient method of collecting samples for COVID-19 testing. The study is based on the hypothesis that saliva collection using the proprietary flavour-stimulated 'Lollipop' swab (LPS) can be a more viable alternative to NPS.
The study aims to establish the comparative efficacy of SARS-Cov-2 infection assessment using Test At Home's proprietary "lollipop" buccal cavity swab (LPS) that simulates oral fluid collection via flavouring and mastication (self-collection) using the contemporary nasal swab collection (by health worker) as standard.
For the present study, 300 pairs of matched nasopharyngeal swab (NPS) (health care worker collected) and simulated oral fluid specimens (self-collected) will be obtained from 150 Coronavirus Disease -19 (COVID-19) positive patients and 150 COVID 19 negative individuals.
Test Method 1: Self-collected Test At Home's proprietary "lollipop" buccal cavity swab with Viral Transport Medium (VTM) will be evaluated using the Standard 'TaqPath™' COVID-19 Conformité Européenne - In Vitro Diagnostic (CE-IVD) Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) which is approved by the Indian Council of Medical Research (ICMR)
Test Method 2: Self-collected Test At Home's proprietary "lollipop" buccal cavity swab with VTM will be evaluated using National University of Singapore (NUS) developed Enzyme Linked Immunosorbent Assay (ELISA) Method.
Active Comparator : Health worker collected Nasopharyngeal Swab (NPS) with VTM which will be evaluated using the Standard TaqPathâ„¢ COVID-19 CE-IVD RT-PCR which is approved by the Indian Council of Medical Research (ICMR).
The diagnostic performance of using NPS and Oral fluids will be statistically compared to determine concordance of positive and negative findings and establish the performance characteristics of the Test Methods.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| COVID Positive | Individuals who have recently tested positive for COVID19 by RTPCR, with active infection. |
| |
| COVID Negative | Individuals who have recently tested negative for COVID19 by RTPCR. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Test At Home's Proprietary "Lollipop" Buccal Cavity Swab | Diagnostic Test | Self-collected Test At Home's proprietary "Lollipop" Buccal Cavity Swab with VTM. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Concordance between buccal cavity swab and contemporary nasal swab. | Three-way concordance of SARS-Cov-2 infection assessment between Test At Home's "Lollipop" buccal cavity swab (assessed by RTPCR and ELISA) and contemporary nasal swab (assessed by RTPCR). | Baseline / Day 0 (At first collection) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult males and females, who have understood the aims, scope, benefits and risks of the study as well as study procedures and provide Informed Consent are eligible to participate. The Study will recruit one hundred and fifty (150) individuals who are known COVID-19 positive (confirmed by RTPCR) and have active infection. The Study will also recruit one hundred and fifty (150) individuals who are known COVID-19 negative (confirmed by RTPCR within the last 7 days).
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Vineet Datta, MD | Contact | +919911110457 | drvineetdatta@datarpgx.com | |
| Dadasaheb Akolkar, PhD | Contact | +917387705888 | dadasaheb.akolkar@datarpgx.com |
| Name | Affiliation | Role |
|---|---|---|
| Vivek Manoharan, PhD | Test At Home Pte. Ltd., Singapore - India. | Principal Investigator |
| Paul Macary, PhD | National University of Singapore | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Datar Cancer Genetics | Nashik | Maharashtra | 422010 | India |
Individual Participant Data (IPD) may be made available to qualified researchers upon written request with declaration of intent to use and after signing of a Confidentiality Agreement / Non Disclosure Agreement (NDA).
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Biological samples collected via nasopharyngeal swaps and 'lollipop' buccal mucosa swabs and used for extraction of viral nucleic acids
|
| Saket Jhajharia, PhD |
| Test At Home Pte. Ltd., Singapore - India |
| Principal Investigator |
| Terence Tan, MBBS | Test At Home Pte. Ltd., Singapore - India. | Principal Investigator |
| Vineet Datta, MD | Datar Cancer Genetics Limited, United Kingdom - India | Principal Investigator |
| Kanupriya Batra, MBA | Test At Home Pte. Ltd., Singapore - India. | Principal Investigator |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |